| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Bis-PEG9-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). ADCs are comprised of an antibody to which an ADC cytotoxin is attached through an ADC linker. The cleavable nature of the PEG9 linker enables the controlled release of the cytotoxic payload at the target site. The compound is also a PEG/Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. The PEG spacer increases the aqueous solubility of the resulting compound.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system. An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
In vitro, Bis-PEG9-NHS ester is used in the synthesis of ADCs and PROTACs. ADCs are comprised of an antibody to which an ADC cytotoxin is attached through an ADC linker. The cleavable nature of the PEG9 linker enables the controlled release of the cytotoxic payload at the target site. The PEG spacer increases the aqueous solubility of the resulting compound. The NHS ester groups can sequentially conjugate with amine-containing proteins, oligonucleotides, etc. |
| ln Vivo |
In vivo, Bis-PEG9-NHS ester enables the controlled release of cytotoxic payloads in experimental models. The cleavable nature of the PEG9 linker ensures that the cytotoxic payload is released at the target site, minimizing systemic toxicity. ADCs constructed with Bis-PEG9-NHS ester have been evaluated in xenograft mouse models of cancer. The compound is a research tool for the development of ADCs and PROTACs for targeted cancer therapy and protein degradation.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Bis-PEG9-NHS ester are not typical, as the compound is a linker rather than a pharmacologically active agent. However, the compound's reactivity with primary amines can be assessed using model proteins such as bovine serum albumin (BSA) or lysozyme. The conjugation reaction is monitored by SDS-PAGE or mass spectrometry. The cleavage of the linker can be assessed in vitro using enzymes or chemical conditions that mimic the intracellular environment.
|
| Cell Assay |
In vitro cell-based assays evaluate the cytotoxicity and target specificity of ADCs constructed with Bis-PEG9-NHS ester in cancer cell lines. Cancer cells are cultured in appropriate media and treated with serial dilutions of the ADC. Cell viability is assessed using MTT or CellTiter-Glo assays after 48-72 hours of treatment. The IC50 values for cytotoxicity are calculated. Target specificity is evaluated by comparing the cytotoxicity of the ADC in target-positive versus target-negative cell lines. Flow cytometry is used to assess ADC binding and internalization.
|
| Animal Protocol |
In vivo, ADCs constructed with Bis-PEG9-NHS ester are evaluated in xenograft mouse models of cancer. Immunocompromised mice bearing subcutaneous tumors are treated with the ADC via intravenous injection at various doses. Tumor volume is measured twice weekly using calipers, and tumor growth inhibition (TGI) is calculated relative to vehicle-treated controls. Pharmacokinetic studies are conducted to determine the ADC's half-life, clearance, and tissue distribution. The safety profile of the ADC is assessed by monitoring body weight, clinical signs, and hematological parameters.
|
| ADME/Pharmacokinetics |
Bis-PEG9-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). It has a molecular weight of 708.71 g/mol. The compound is soluble in organic solvents. It should be stored at -20°C under desiccated conditions. The PEG spacer increases the aqueous solubility of the resulting compound. The NHS ester groups can sequentially conjugate with amine-containing proteins, oligonucleotides, etc.
|
| Toxicity/Toxicokinetics |
The toxicity of Bis-PEG9-NHS ester is primarily associated with its reactivity as a crosslinking agent. The compound can cause skin and eye irritation upon contact. Inhalation of the compound may cause respiratory irritation. In preclinical studies, the compound has shown low acute toxicity, but its reactivity with proteins raises concerns about potential off-target effects. The compound should be handled with appropriate personal protective equipment in a well-ventilated area. For research use only, not for human use.
|
| References | |
| Additional Infomation |
Bis-PEG9-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). It is also a PEG/Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. The compound contains two NHS ester groups that react with primary amines to form stable amide bonds. The PEG spacer increases the aqueous solubility of the resulting compound. Bis-PEG9-NHS ester is a versatile tool for bioconjugation and targeted protein degradation.
|
| Molecular Formula |
C30H48N2O17
|
|---|---|
| Molecular Weight |
708.7053
|
| Exact Mass |
708.295
|
| CAS # |
1008402-79-6
|
| PubChem CID |
77078480
|
| Appearance |
Colorless to light yellow viscous liquid
|
| LogP |
-3.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
34
|
| Heavy Atom Count |
49
|
| Complexity |
890
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])C(=O)ON1C(C([H])([H])C([H])([H])C1=O)=O)=O)N1C(C([H])([H])C([H])([H])C1=O)=O
|
| InChi Key |
CQWLSZJYTZVHMU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H48N2O17/c33-25-1-2-26(34)31(25)48-29(37)5-7-39-9-11-41-13-15-43-17-19-45-21-23-47-24-22-46-20-18-44-16-14-42-12-10-40-8-6-30(38)49-32-27(35)3-4-28(32)36/h1-24H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~141.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4110 mL | 7.0551 mL | 14.1101 mL | |
| 5 mM | 0.2822 mL | 1.4110 mL | 2.8220 mL | |
| 10 mM | 0.1411 mL | 0.7055 mL | 1.4110 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
